• Growth and revenue guidance: The company is guiding for 14% to 15% revenue growth in FY27 after achieving 17% to 18% growth in Q1, driven by 10% to 11% patient volume growth and a 6% to 7% product mix increase.
• Margin and pricing strategy: Metropolis expects a 100 to 150 basis points margin expansion in FY27 without factoring in price hikes. Any potential price increases were paused until September following GST changes and will be evaluated going forward.
• Specialty test expansion: The company aims to increase specialty tests from 40% to 45% of total revenue, expecting the segment to outpace average company growth with roughly 19% to 20% growth.
• Mini hub rollout: Metropolis plans to maintain capex at roughly 4% of sales as it converts several of its 800 company-owned centers into mini hubs offering basic radiology, vital checks, and nutritional services for retail, corporate, and insurance clients.